Abstract:BACKGROUND:In this study the expression of COX-2 both in lung cancer tissues and tissues of benign disease of the lung is compared to explore the effect of COX-2 on occurrence and development of non-small cell lung cancer (NSCLC), and the relationship between COX-2 expression and clinical characteristics of patients with NSCLC. METHODS:The COX-2 expression, vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) were detected in 78 NSCLC lung cancer tissues and 14 benign tissues of the lung by immunohistochemical method. RESULTS:Expression of COX-2 protein was significantly higher in cancer tissues (69.2%, 54/78) than paired noncancerous tissues (14.3%, 2/14)(Chi-square=15.044, P < 0.01). There was significant difference of MVD between COX-2 positive lung cancers (19.41±8.56) and negative ones(12.00±5.37)(t=3.906, P < 0.01). There was no significant relationship between COX-2 protein expression and patients' age, sex, TNM stages and smoking status (P > 0.05); for different pathological types, COX-2 protein expression was remarkably higher in adenocarcinoma (88.9%, 32/36) than that in squamous cell carcinoma (50.0%, 20/40) (Chi-square=13.262, P < 0.01); and for squamous cell carcimoma it was significantly higher in low differentiated ones (81.0%, 17/21) than that in high differentiated ones (15.8%, 3/19) (Chi-square=16.942,P < 0.01); for adenocarcinoma it was also remarkably higher in low differentiated ones (100.0%, 18/18) than that in high differentiated ones ( 77.8% , 14/18) (Chi-square=6.046, P < 0.05).The expressions of COX-2 and VEGF in NSCLC were significantly positively correlated (r=0.509, P < 0.01), so were the expressions of VEGF and MVD (r=0.324, P < 0.01), and the expressions of COX-2 and MVD (r=0.477, P < 0.01). Controlling for VEGF, there still was significant correlation between COX-2 and MVD (r=0.383, P < 0.01). CONCLUSIONS:The present study suggests that there is overexpression of COX-2 in lung cancer, which is closely related to angiogenesis of lung cancer. Further studies, therefore, are needed to find the exact mechanisms.

Cyclooxygenase-2 Expression Is Up-Regulated In Human Pancreatic Cancer

Expression of cyclooxygenase 2 in colorectal cancer

Cyclooxygenase-2 Induces Angiogenesis in Pancreatic Cancer Mediated by Prostaglandin E-2

Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer

Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs

Cyclooxygenase-2 Expression in Thyroid Nodules.

Expression of cyclooxygenase-2 (COX-2) in human astrocytoma

Cyclo-Oxygenase 2 Up-Regulates the Effect of Multidrug Resistance

Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.

Expression of COX-2 in uterine adenomyosis and its clinical significance

[Study of COX-2 Expression and Angiogenesis in Non-Small Cell Lung Cancer].

MFN2 Provides Antitumor Efficacy in Pancreatic Cancer Cells

Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray.

Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer

Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer

Cell Intrinsic Role of Cox-2 in Pancreatic Cancer Development

Bile acids induce cyclooxygenase-2 expression in human pancreatic cancer cell lines

Expression of COX-1 and COX-2 in colorectal adenoma

Expression of Cyclooxygenase-2 in Gastric Cancer and Its Relation to Liver Metastasis and Long-Term Prognosis

COX-2 expression and tumor angiogenesis in colorectal cancer.

Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma